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AbstrAct
Glioblastoma is an intrinsic brain tumour thought to arise 
from neuroglial progenitor cells. Its incidence increases 
steadily with age. Males are moderately more often 
affected. Genetic predisposition and exposure to irradiation 
in childhood are the only established risk factors which, 
however, account only for a very small proportion of 
glioblastomas. Surgery as safely feasible not only to allow 
for tissue diagnosis but also to reduce tumour volume 
is usually the first therapeutic measure. Radiotherapy 
delivered to the tumour region with a safety margin 
has been demonstrated to roughly double survival four 
decades ago. Temozolomide given during radiotherapy 
followed by six cycles of maintenance chemotherapy 
was the first and so far only pharmacological treatment 
shown to prolong survival. Adding tumour-treating fields 
during maintenance, temozolomide chemotherapy has 
been reported to prolong survival. There is little evidence 
that any intervention at relapse improves outcome, 
but nitrosourea-based chemotherapy, commonly 
lomustine, is probably the most agreed on standard of 
care. Bevacizumab prolongs progression-free survival 
and probably quality of life in the first line or recurrent 
setting, but not overall survival, and is therefore not 
approved in the European Union. Immunotherapy remains 
experimental. Drugs in advanced clinical development 
include the programmed death 1 antibody, nivolumab, 
the antibody drug conjugate depatuxizumab directed to 
the epidermal growth factor receptor and the proteasome 
inhibitor marizomib.
Definition anD Diagnosis
The diagnosis of glioblastoma requires the 
histological and molecular genetic study of 
tumour tissue obtained during open tumour 
resection or biopsy. Morphologically, glioblas-
toma is defined as a glial brain tumour with 
features of malignancy that include angiogen-
esis and focal necrosis. The new WHO classifi-
cation recognises, in addition to classical glio-
blastoma, giant cell glioblastoma, gliosarcoma 
and epithelioid glioblastoma as histologically 
defined variants. Half of the rare epithelioid 
glioblastomas show BRAFV600E mutations.1 So 
far treatment recommendations do not vary 
for these glioblastoma variants.
Furthermore, classical glioblastoma does 
not exhibit isocitrate dehydrogenase (IDH) 1 
or 2 mutations; tumours carrying such muta-
tions show a less aggressive clinical course 
and will probably no longer be labelled glio-
blastomas in future revisions of the WHO 
classification. In contrast, it has been proposed 
to consider glial tumours without IDH 1 or 
2 mutations which do not fulfil histological 
criteria of glioblastoma as tumours equivalent 
to glioblastoma, for example, in the context 
of a clinical trial if they fulfill one of the 
following criteria: epidermal growth factor 
receptor amplification, whole chromosome 
7 gain combined with whole chromosome 
10 loss or telomerase reverse transcriptase 
promoter mutation.2 Specifically in glio-
blastoma without IDH mutation and thus 
commonly without CpG island methylator 
phenotype, methylation of the promoter 
region of the O6-methylguanine DNA methyl-
transferase (MGMT) gene, tested by methyl-
ation-specific PCR or by pyrosequencing, has 
been established as a predictive biomarker for 
benefit from alkylating agent chemotherapy. 
Extensive efforts have been undertaken 
to define cut-offs to dissect what extent of 
MGMT promoter methylation is required to 
confer benefit from alkylating chemotherapy 
and which CpG of the promoter region 
should be assessed. With methylation-specific 
PCR, there is a grey zone in between truly 
unmethylated and methylated, resulting in 
a recommendation of a cut-off of 1.27 (Log2 
(1000×(MGMT+1)/ACTB) plus a safety 
margin of −0.28). With pyrosequencing, the 
cut-off for being methylated is usually set at 
7%–25%.3 Young age and good performance 
status are therapy-independent positive prog-
nostic factors. Figure 1 provides an algorithm 
how to approach glioblastoma that is consis-
tent with the 2017 guideline of the European 
Association of Neuro-Oncology.4
newly DiagnoseD setting
surgery
Maximum surgical resection using micro-
surgical techniques as safely feasible is 
considered standard of care, although the 
role of surgery has been difficult to define 
in controlled clinical trials. The proof-of-
concept trial for fluorescence-guided resec-
tion indicated improved progression-free 
survival in patients who had a gross total 
resection.5 The extent of surgery should be 
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Figure 1 Therapeutic approach to glioblastoma. GTR, gross total resection; IDH, isocitrate dehydrogenase; KPS, Karnofsky 
performance score; MGMT, O6-methylguanine DNA methyltransferase; RT, radiation therapy; TMZ, temozolomide.
verified by contrast-enhanced MRI within 24–72 hours 
of surgery. Although the volume of residual tumour 
after surgery negatively correlates with outcome, it has 
remained impossible to clarify whether extent of resec-
tion improves outcome or whether tumours amenable 
to gross total resection have a different, less malignant 
course of disease. Still, we support efforts at gross total 
tumour resection and do not believe that a randomised 
clinical trial to demonstrate benefit from this interven-
tion can be ethically justified. If microsurgical resection 
is not feasible due to medical reasons or refusal of the 
patient, an image-guided stereotactic serial biopsy can 
provide sufficient material for both histological as well as 
molecular diagnosis to guide therapeutic management.6 
Some centres prefer open biopsies to get more tissue. 
Treatment decisions without obtaining tissue for a histo-
logical diagnosis are strongly discouraged.
Radiotherapy
Involved field radiotherapy has been established as a 
standard of care for glioblastoma more than 40 years 
ago. It improves local control and probably roughly 
doubles survival. Standard radiotherapy is delivered in 
1.8–2 Gy fractions to a total dose of 54–60 Gy. Hypof-
ractionated radiotherapy with a biologically equivalent 
dose of 40 Gy given in 15 fractions of 2.67 Gy has been 
established as a valid option for older patients and for 
patients with limited life expectancy because of poor 
prognostic factors.7 Amino acid positron emission tomog-
raphy is currently explored as a tool to better delineate 
the target volume of radiotherapy. Neither novel tech-
niques of administering irradiation nor the combination 
of radiotherapy with candidate radiosensitising agents 
have shown superior efficacy over standard fractionated 
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radiotherapy. Radiotherapy may be withheld in elderly 
patients or patients with poor performance status if the 
tumour exhibits MGMT promoter methylation; such 
patients may be treated with temozolomide alone.8
Pharmacotherapy
Temozolomide chemotherapy during radiotherapy (75 
mg/m2 daily) followed by six cycles of maintenance 
chemotherapy (150–200 mg/m2, 5/28 days) is standard 
of care for the majority of patients with glioblastoma.9 10 
Limitations include major comorbidities such as haema-
tological or hepatic disease or infection. Myelosuppres-
sion, notably thrombocytopenia, is the most common 
side effect. There is no evidence that changing the dosing 
of the temozolomide regimen or prolonging its admin-
istration beyond 6 months improve survival.4 Benefit 
from temozolomide is largely restricted to patients with 
tumours with MGMT promoter methylation.11
tumour-treating fields
Tumour-treating fields involve the focal delivery of 
low-intensity, intermediate-frequency (200 kHz) alter-
nating electrical fields to the tumour-bearing brain that 
are postulated to inhibit cell cycle progression through 
metaphase. An open label randomised trial of tumour-
treating fields administered from the initiation of mainte-
nance temozolomide reported superior progression-free 
survival and overall survival compared with temozolo-
mide alone.12 While this treatment is safe and usually well 
tolerated except for local skin reactions, its acceptance 
by patients, relatives and healthcare professionals in most 
parts of Europe is low. Furthermore, reimbursement 
remains a critically debated issue in most countries.
Best supportive care
This strategy may be selected for patients with extensive 
or multifocal lesions in poor general or neurological 
condition and patients who cannot consent to further 
treatment once the diagnosis of glioblastoma has been 
established.
ReCuRRent setting
Standards of care at recurrence are far less well defined 
than in the newly diagnosed setting. Up to half of patients 
with glioblastoma may not qualify for salvage treatment.13 
Repeat surgery should be offered if a gross total resec-
tion seems feasible and if the time from first surgical 
intervention is longer than approximately 6 months.14 
Reirradiation can be offered to patients with circum-
scribed recurrences. Neither for surgery nor for radio-
therapy, a randomised trial to document prolongation of 
survival has been conducted. Tumour-treating fields were 
not superior to best physicians’ choice in the recurrent 
setting.
Most patients with recurrent glioblastoma who are 
eligible for salvage therapy are treated with a second 
course of alkylating agent chemotherapy, mostly lomus-
tine (CCNU). The strategy of temozolomide rechallenge 
is less frequently pursued today than a few years ago. 
Either alkylating agent is unlikely to provide benefit in 
patients with tumours without MGMT promoter methyl-
ation. Bevacizumab as a single agent was approved in the 
USA and various other countries, although not the Euro-
pean Union, based on response rates and progression-free 
survival rates at 6 months interpreted to be superior to 
historical controls. Yet, the combination of bevacizumab 
with lomustine prolonged progression-free survival only, 
but not overall survival, compared with lomustine alone.15 
The differential interpretation of the significance and 
validity of progression-free survival explains the different 
approval status of bevacizumab in recurrent glioblastoma. 
Depending on local availability, the combination of beva-
cizumab and lomustine is a treatment option in particular 
in patients with rapidly progressing disease. Much more 
commonly, bevacizumab where available is now used 
in symptomatic patients at later recurrences. A popula-
tion-based analysis has not been able to find evidence 
that the approval of bevacizumab prolonged survival on a 
population level.13
follow-uP
Neurological evaluation and MRI at least every 3 months 
are the central tools to assess benefit from therapy and for 
monitoring during follow-up. Pseudoprogression remains 
a concern especially within the first 3–6 months after 
completion of radiotherapy. Advanced MRI and positron 
emission tomography are explored to provide guidance, 
but the most important consideration in patients with 
potential pseudoprogression is not to discontinue a poten-
tially active treatment too early. Throughout the course of 
disease, control of symptomatic seizures and detection, 
treatment and secondary prevention of venous thrombo-
embolic events remain important tasks. Primary seizure 
prophylaxis with antiepileptic drugs is not indicated and 
steroids should be given to symptomatic patients only, at 
the lowest dose and for the shortest time feasible.
CuRRent DeveloPments
Data from four phase III trials may change clinical practice 
in the upcoming years. CheckMate 498 (NCT02617589) 
and CheckMate 548 (NCT02667587) explored nivolumab 
in newly diagnosed patients with glioblastoma without and 
with MGMT promoter methylation. Depatuxizumab, an 
antibody drug conjugate, was tested in the same setting in 
estimated glomerular filtration rate-amplied glioblastoma 
(NCT02573324). These trials have completed accrual and 
data should become available in 2019. The proteasome 
inhibitor marizomib is examined in newly diagnosed glio-
blastoma within the European Organisation for Research 
and Treatment of Cancer trial 1709 (NCT03345095).
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